Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. ARIX.L Share Price
  4. ARIX.L Share Regulatory News
  5. Director/PDMR Shareholding

Pin to quick picksARIX.L Regulatory News (ARIX)

ARIX.L Information
  • There is currently no data for ARIX

Director/PDMR Shareholding

5 Oct 2022 07:00

Arix Bioscience PLC (ARIX)


Director/PDMR Shareholding

05-Oct-2022 / 07:00 GMT/BST

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc
("Company")

Director/PDMR Shareholding

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 100,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 4 October 2022 at a price of 102.94 pence per Share.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Peregrine Moncreiffe

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Director and Chair of the Board

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

  c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

 

102.94

100,000.00

 

d)

 

Aggregated information

 

- Aggregated volume

N/A single transaction

- Price

£102,942.50

e)

 

Date of the transaction

 

04 October 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

For further information please contact:
Kin Company Secretarial Limited, Company Secretary
+44 20 8819 6486


ISIN: GB00BD045071
Category Code: DSH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 192396
EQS News ID: 1456713

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1456713&application_name=news&site_id=london_south_east
3456789101112
Date   Source Headline
1st Oct 20202:40 pmEQSLogicBio announces pricing of public offering
21st Sep 202011:20 amEQSHardman & Co Research: Arix Bioscience (ARIX): Realising the valuation disconnect
18th Sep 20208:57 amEQSArix Bioscience PLC: Autolus presents additional AUTO3 data in DLBCL
8th Sep 20207:00 amEQSArix Bioscience PLC: Interim Results for the Six Months Ended 30 June 2020
13th Aug 20207:07 amPRNNotice of Results
10th Aug 202012:49 pmPRNLogicBio announces IND clearance for LB-001
31st Jul 20202:06 pmRNSSecond Price Monitoring Extn
31st Jul 20202:00 pmRNSPrice Monitoring Extension
31st Jul 20207:01 amPRNTotal Voting Rights
20th Jul 20201:28 pmPRNAmplyx announces positive Phase 2 data
10th Jul 20207:53 amPRNAtox Bio plans NDA submission for Q3 2020
8th Jul 20201:27 pmPRNVelosBio completes $137 million Series B financing
1st Jul 20207:00 amPRNDirector/PDMR Shareholding, Issue of Ordinary Shares
1st Jul 20207:00 amPRNDirector/PDMR Shareholding, Issue of Ordinary Shares
12th Jun 20202:24 pmPRNAura presents updated AU-011 clinical data at ARVO 2020
12th Jun 20201:34 pmPRNImara presents positive interim Phase 2a data at EHA
12th Jun 20209:13 amPRNAutolus AUTO1 and AUTO3 data at EHA
8th Jun 20207:08 amPRNArix announces strategic and operational update
4th Jun 20205:42 pmPRNResults of Annual General Meeting
1st Jun 20202:57 pmPRNIterum announces topline Phase 3 data in complicated UTI
29th May 20201:38 pmPRNHarpoon presents interim Phase 1 data for HPN424
29th May 20201:06 pmPRNAutolus presents additional AUTO3 data in DLBCL
27th May 20204:40 pmRNSSecond Price Monitoring Extn
27th May 20204:35 pmRNSPrice Monitoring Extension
20th May 20207:00 amPRNAmplyx closes $53 million Series C extension
19th May 20209:35 amEQSHardman & Co Research: Arix Bioscience (ARIX): 1Q'20 portfolio update
12th May 20207:00 amPRNNotice of Annual General Meeting
28th Apr 20209:23 amPRNPharmaxis announces new data in myelofibrosis
27th Apr 20201:12 pmPRNHarpoon doses first patient in multiple myeloma trial
23rd Apr 20207:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): Resetting the stage
17th Apr 20202:59 pmPRNDirector/PDMR Shareholding
16th Apr 20201:08 pmPRNAutolus announces FDA acceptance of IND application
6th Apr 20207:00 amPRNChanges to Board of Directors and executive leadership
19th Mar 202010:31 amEQSHardman & Co Research: Arix Bioscience (ARIX): Fiscal 2019 - moving with the times
16th Mar 20207:00 amPRNDirector/PDMR Shareholding
12th Mar 20207:11 amPRNImara prices Nasdaq IPO
10th Mar 20207:00 amPRNAnnual Results for the year ended 31 December 2019
9th Mar 202012:00 pmPRNDr Roberto Iacone appointed as EiR
3rd Mar 202012:18 pmPRNUpdate on Imara proposed IPO in the United States
3rd Mar 20207:30 amEQSHardman & Co Research: Q&A with Q&A with Dr Dorothea Hill on Arix Bioscience (ARIX)
27th Feb 202012:00 pmPRNNotice of Results
24th Feb 20201:26 pmPRNAura announces updated Phase 1b/2 clinical data
19th Feb 20207:30 amEQSHardman & Co Research: Arix Bioscience (ARIX) - Initiation of coverage: With high risk can come high reward
17th Feb 20207:00 amPRNImara files for proposed IPO in the United States
30th Jan 202012:08 pmPRNAutolus presents encouraging additional AUTO3 data
27th Jan 20207:00 amPRNArix co-founds Quench Bio with Series A financing
23rd Jan 20207:00 amPRNAutolus announces pricing of public offering
17th Jan 20201:15 pmPRNIterum announces $52 million private placement
18th Dec 201910:00 amPRNPharmaxis business update
17th Dec 201910:57 amPRNBoard changes
3456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
BEEP
BEEP.L
LSE
0.00%
JPEC
JPEC.L
LSE
0.00%
ASCI
ASCI.L
LSE
0.00%
FJV
Fidelity Japan Trust
LSE
0.00%
TDE
TDE.L
LSE
0.00%
Trending
ITM
Itm Power
LSE
-10.85%
AVCT
Avacta Group
LSE
2.14%
NANO
Nanoco
LSE
-10.69%
PPP
Pennpetro Energy
LSE
0.00%
LLOY
Lloyds
LSE
-1.33%